Atomo Diagnostics - Logomark

Atomo Diagnostics Featured in The Australian

Atomo Diagnostics (ASX:AT1) features in Nadine McGrath’s coverage of ASX-listed healthcare companies and the Northern Hemisphere respiratory season, published by Stockhead and carried in The Australian on 19 November 2026.

The article highlights Atomo’s role in the FebriDx point-of-care test through its proprietary Pascal cassette technology, connecting the platform’s integrated design with the test’s expanding US commercial rollout.

Atomo’s Pascal Platform Supports FebriDx Testing

According to the article, Atomo supplies the patented Pascal cassette technology used in FebriDx. Pascal brings blood collection and testing together in an integrated device.

FebriDx supports clinicians assessing people with respiratory symptoms by helping distinguish bacterial from non-bacterial infections. It does not diagnose influenza specifically.

The report notes that FebriDx received US Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver. These regulatory milestones relate to FebriDx, the test that incorporates Atomo’s Pascal cassette.

US Clinical Adoption and Atomo’s Supply Role

The coverage describes plans to introduce FebriDx across additional US urgent care locations. For Atomo, the commercial opportunity is linked to supplying the Pascal technology used in those tests.

The article reports that increased commercial FebriDx sales are expected to support demand for Pascal. This is an opportunity associated with adoption and test utilisation, rather than a guarantee of future sales.

Read the Full Media Coverage

For the complete report, read Nadine McGrath’s article, “ASX healthcare companies on frontline of Northern Hemisphere flu season”, on Stockhead.

This post provides an original summary of the coverage supplied from The Australian. The full article remains with its publisher.

Leave a Comment